Was speaking with someone about Daltons LinkedIn post yesterday on how it could have been worded; and they thought that ("QUOTE"
My guess and hope some of what he’s working on is under confidentiality or NDA!!!!)If a binding deal actually exists, the law requires it to be filed. If it hasn't been filed on an official portal, it means either: The deal is still in unexecuted, non-binding talks (meaning it's not a done deal), or no formal agreement has been reached at all.
Neither an NDA nor a confidentiality agreement prevents an CEO / Executive from disclosing material business deals—in fact, public market rules and federal securities laws mandate it. NDAs exist to protect trade secrets during negotiations, but once a deal is actually executed, public reporting duties supersede private confidentiality agreements.
From all public information available this has been in the works since early-mid 2025, why wasn't the deals, manufacturing, licensing NDC any other agreements already signed taken care of before the Capital Deck was launched, only thing in the Capital Deck mentioned was a MOU finalized April 2026, which is nothing more than an Agreement to Agree.
The MOU signed in April 2026 confirms that the parties were still in preliminary talks at that point, meaning none of the involved entities (Univec, CentennialRx, 11Three, or Remy Biosciences) were legally bound to produce, package, or distribute a single RELIEFTA™ patch when the pitch deck was put in motion.
Has something happened in the negotiations, hope it doesn't turn into ongoing social media promises as from the past, at this time and point several thousand dollars have been spent.
PL
My guess and hope some of what he’s working on is under confidentiality or NDA!!!!)If a binding deal actually exists, the law requires it to be filed. If it hasn't been filed on an official portal, it means either: The deal is still in unexecuted, non-binding talks (meaning it's not a done deal), or no formal agreement has been reached at all. Neither an NDA nor a confidentiality agreement prevents an CEO / Executive from disclosing material business deals—in fact, public market rules and federal securities laws mandate it. NDAs exist to protect trade secrets during negotiations, but once a deal is actually executed, public reporting duties supersede private confidentiality agreements.
From all public information available this has been in the works since early-mid 2025, why wasn't the deals, manufacturing, licensing NDC any other agreements already signed taken care of before the Capital Deck was launched, only thing in the Capital Deck mentioned was a MOU finalized April 2026, which is nothing more than an Agreement to Agree.
The MOU signed in April 2026 confirms that the parties were still in preliminary talks at that point, meaning none of the involved entities (Univec, CentennialRx, 11Three, or Remy Biosciences) were legally bound to produce, package, or distribute a single RELIEFTA™ patch when the pitch deck was put in motion.
Has something happened in the negotiations, hope it doesn't turn into ongoing social media promises as from the past, at this time and point several thousand dollars have been spent.
PL
